PT2531187E - Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc) - Google Patents

Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc) Download PDF

Info

Publication number
PT2531187E
PT2531187E PT117016832T PT11701683T PT2531187E PT 2531187 E PT2531187 E PT 2531187E PT 117016832 T PT117016832 T PT 117016832T PT 11701683 T PT11701683 T PT 11701683T PT 2531187 E PT2531187 E PT 2531187E
Authority
PT
Portugal
Prior art keywords
sgc
treatment
combination
cystic fibrosis
stimulators
Prior art date
Application number
PT117016832T
Other languages
English (en)
Inventor
Stasch Dr Johannes-Peter
Peter Sandner
Georges Von Degenfeld
Sandner Peter
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2531187(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of PT2531187E publication Critical patent/PT2531187E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
PT117016832T 2010-02-05 2011-02-03 Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc) PT2531187E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05

Publications (1)

Publication Number Publication Date
PT2531187E true PT2531187E (pt) 2015-10-20

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117016832T PT2531187E (pt) 2010-02-05 2011-02-03 Estimuladores de sgc ou ativadores de sgc sozinhos e em combinação com inibidores de pde5 para o tratamento de fibrose cística (fc)

Country Status (32)

Country Link
US (1) US20130035340A1 (pt)
EP (1) EP2531187B1 (pt)
JP (2) JP6143461B2 (pt)
KR (1) KR101793304B1 (pt)
CN (3) CN104800219A (pt)
AU (1) AU2011212521B2 (pt)
BR (1) BR112012019666A2 (pt)
CA (1) CA2788969C (pt)
CL (1) CL2012002173A1 (pt)
CR (1) CR20120408A (pt)
CY (1) CY1116878T1 (pt)
DK (1) DK2531187T3 (pt)
EA (1) EA025177B1 (pt)
ES (1) ES2548394T3 (pt)
HK (1) HK1212892A1 (pt)
HR (1) HRP20151187T1 (pt)
HU (1) HUE028008T2 (pt)
IL (1) IL221012B (pt)
MA (1) MA33984B1 (pt)
MX (1) MX342944B (pt)
MY (2) MY159697A (pt)
NZ (1) NZ601612A (pt)
PL (1) PL2531187T3 (pt)
PT (1) PT2531187E (pt)
RS (1) RS54336B1 (pt)
SG (1) SG182819A1 (pt)
SI (1) SI2531187T1 (pt)
SM (1) SMT201500286B (pt)
TN (1) TN2012000397A1 (pt)
UA (1) UA112962C2 (pt)
WO (1) WO2011095534A1 (pt)
ZA (1) ZA201205532B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548394T3 (es) * 2010-02-05 2015-10-16 Adverio Pharma Gmbh Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗***性硬化症(SSc)的用途
EP2585055A1 (de) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
EP2892891B1 (en) * 2012-09-07 2019-07-31 Boehringer Ingelheim International GmbH Alkoxy pyrazoles as soluble guanylate cyclase activators
EP3024455A1 (en) * 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EA032972B1 (ru) 2014-07-22 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA3008776A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
EP3554506B1 (en) 2016-12-16 2021-04-28 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as cftr potentiators
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP1095016B1 (en) * 1998-07-08 2005-11-09 Sanofi-Aventis Deutschland GmbH Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2009068652A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
TW200938529A (en) 2007-12-03 2009-09-16 Smithkline Beecham Corp Compounds
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
CA2726913C (en) * 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2548394T3 (es) * 2010-02-05 2015-10-16 Adverio Pharma Gmbh Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística

Also Published As

Publication number Publication date
IL221012B (en) 2018-01-31
NZ601612A (en) 2014-08-29
MY160856A (en) 2017-03-31
EP2531187B1 (en) 2015-08-12
KR101793304B1 (ko) 2017-11-02
BR112012019666A2 (pt) 2017-06-20
ZA201205532B (en) 2014-12-23
AU2011212521A1 (en) 2012-08-16
UA112962C2 (uk) 2016-11-25
KR20120125276A (ko) 2012-11-14
CN102770133A (zh) 2012-11-07
PL2531187T3 (pl) 2016-01-29
WO2011095534A1 (en) 2011-08-11
HK1212892A1 (zh) 2016-06-24
JP6270907B2 (ja) 2018-01-31
CA2788969C (en) 2017-11-21
SI2531187T1 (sl) 2016-01-29
CA2788969A1 (en) 2011-08-11
DK2531187T3 (en) 2015-11-09
EP2531187A1 (en) 2012-12-12
ES2548394T3 (es) 2015-10-16
MX2012009011A (es) 2012-09-07
RS54336B1 (en) 2016-02-29
CN107929271A (zh) 2018-04-20
CY1116878T1 (el) 2017-04-05
JP2016155857A (ja) 2016-09-01
HRP20151187T1 (hr) 2015-12-04
IL221012A0 (en) 2012-09-24
EA201290702A1 (ru) 2013-02-28
CN104800219A (zh) 2015-07-29
US20130035340A1 (en) 2013-02-07
HUE028008T2 (en) 2016-11-28
JP6143461B2 (ja) 2017-06-07
MX342944B (es) 2016-10-18
SG182819A1 (en) 2012-09-27
MA33984B1 (fr) 2013-02-01
SMT201500286B (it) 2016-01-08
CL2012002173A1 (es) 2013-05-17
AU2011212521B2 (en) 2015-11-19
TN2012000397A1 (en) 2014-01-30
JP2013518851A (ja) 2013-05-23
EA025177B1 (ru) 2016-11-30
MY159697A (en) 2017-01-13
CR20120408A (es) 2013-02-12

Similar Documents

Publication Publication Date Title
HK1212892A1 (zh) 用於治療囊性纖維化的單獨和與 抑制劑組合的 刺激劑或 激活劑
ME02207B (me) UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
IL213857A0 (en) Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
ZA201304159B (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
IL235358A0 (en) Tritocholine for use in the treatment of cystic fibrosis
HK1199881A1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease -4-
IL214244A0 (en) Scriptaid isosteres and their use in therapy
IL219768A0 (en) Drug combination with thebromine and its use in therapy
PT2590509T (pt) Método para a preparação e utilização de biocidas enriquecidos em radicais ativos antes da utilização
IL219769A0 (en) Drug combination with theromine and its use in therapy
IL212208A0 (en) Use of ammonium chloride in therapy
ZA201304460B (en) Novel bacterium and extracts of said bacterium and the use of same in therapy
PT2670769T (pt) R2r1/2 em diagnóstico e terapêutica
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
GB201000499D0 (en) Treatment of cystic fibrosis
HK1209073A1 (en) Plod-2 stimulators and their use in the treatment of skin plod-2
ZA201403477B (en) Apricitabine and pi combination therapy
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
AU2011904834A0 (en) Apricitabine and NRTI combination therapy
GB201021425D0 (en) Drug composition and its use in therapy
GB201019972D0 (en) Drug composition and its use in therapy
GB201019971D0 (en) Drug composition and its use in therapy
GB201015789D0 (en) Peptides and their use in the treatment
GB0920267D0 (en) Drug combination and its use in therapy
AU2011904831A0 (en) Apricitabine and PI combination therapy